Launch of the WuXia293 Platform by WuXi Biologics is Announced
WuXia293: A Game-Changer in Biologics Manufacturing
WuXi Biologics, a leading biologics manufacturing company, has unveiled a new platform called WuXia293. This innovative cell line, developed using its proprietary HEK293 cells, stands as a powerful testament to WuXi Biologics' commitment to its vision that every biologic can be made [2].
WuXia293 offers several advantages over traditional CHO cell lines, particularly for developing difficult-to-express molecules. It provides high titers, improved product purity, and a reduction or elimination of truncation issues, all while maintaining stable expression over long-term cell passages [1][3].
In contrast, CHO cells, while widely used and known for high titers and good manufacturability, often face challenges with complex modalities, including low titer levels and truncation problems due to some CHO-specific host cell proteins that can degrade protein quality and function [1].
Here's a comparison of key features between WuXia293 (HEK293 platform) and CHO cells:
| Feature | WuXia293 (HEK293 platform) | CHO Cells | |------------------------------------|-------------------------------------------------------------|------------------------------------------------------| | Expression titer | High titers up to 5.0 g/L | High titers, but sometimes lower for complex molecules| | Truncation issues | Significantly alleviated or eliminated | Present, affecting product quality | | Product purity | Improved | May be compromised by CHO host cell proteins | | Stability in passages | Stable expression and consistent quality during long-term passages | Generally stable but sometimes less consistent with complex molecules | | Compatibility with complex molecules | Enhanced developability and manufacturability | May have compatibility issues with complex biologics |
WuXia293 demonstrates high titers, robust stability, and superior quality, enhancing the developability and manufacturability of these molecules. It is fully compatible with the WuXi Biologics process, as shown by its robust growth and balanced metabolism [1].
Moreover, WuXia293 enables scalable clinical and commercial manufacturing at 2000L scale for fed-batch and 1000L scale for perfusion. It offers flexible scalability in culture scale for various research and pre-clinical development stages [1].
The WuXia293 launch strengthens the service capabilities of WuXi Biologics' WuXiaTM platform family. The company offers a comprehensive suite of services for the WuXia293 platform, including cell bank testing and clearance validation [1].
Dr. Chris Chen, CEO of WuXi Biologics, commented that WuXia293 significantly enhances the development of advanced therapeutics [2]. The launch of WuXia293 reaffirms WuXi Biologics' promise to enable its clients in accelerating the delivery of innovative biologics to patients worldwide [2].
The WuXiaTM platform has already derived multiple cell line development platforms, including WuXia PlusTM and WuXia RidGSTM [1]. With the addition of WuXia293, WuXi Biologics continues to push the boundaries of what is possible in biologics manufacturing.
[1] WuXi Biologics. (2022). WuXi Biologics Launches New HEK293 Cell Line Platform, WuXia293, for Developing and Manufacturing Difficult-to-Express Molecules. [online] Available at: https://www.wuxibiologics.com/en/news-events/press-releases/wuxi-biologics-launches-new-hek293-cell-line-platform-wuxia293-for-developing-and-manufacturing-difficult-to-express-molecules-1327
[2] WuXi Biologics. (2022). WuXia293 Significantly Enhances the Development of Advanced Therapeutics. [online] Available at: https://www.wuxibiologics.com/en/news-events/press-releases/wuxia293-significantly-enhances-the-development-of-advanced-therapeutics-1328
[3] WuXi Biologics. (2022). WuXia293: A High-Performance HEK293 Cell Line Platform for Manufacturing Advanced Therapeutics. [online] Available at: https://www.wuxibiologics.com/en/news-events/press-releases/wuxia293-a-high-performance-hek293-cell-line-platform-for-manufacturing-advanced-therapeutics-1329
